Celon Pharma S.A. (WSE: CLN)

Celon Pharma Statistics

Total Valuation

Celon Pharma has a market cap or net worth of PLN 1.35 billion. The enterprise value is 1.26 billion.

Market Cap	1.35B
Enterprise Value	1.26B

Important Dates

The next estimated earnings date is Wednesday, April 16, 2025.

Earnings Date	Apr 16, 2025
Ex-Dividend Date	Jun 27, 2024

Share Statistics

Celon Pharma has 53.86 million shares outstanding. The number of shares has increased by 4.00% in one year.

Current Share Class	n/a
Shares Outstanding	53.86M
Shares Change (YoY)	+4.00%
Shares Change (QoQ)	+0.82%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	14.84%
Float	23.82M

Valuation Ratios

The trailing PE ratio is 71.69 and the forward PE ratio is 24.51.

PE Ratio	71.69
Forward PE	24.51
PS Ratio	6.33
PB Ratio	2.61
P/TBV Ratio	2.66
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.17, with an EV/FCF ratio of -38.31.

EV / Earnings	67.93
EV / Sales	6.00
EV / EBITDA	20.17
EV / EBIT	57.49
EV / FCF	-38.31

Financial Position

The company has a current ratio of 2.67, with a Debt / Equity ratio of 0.03.

Current Ratio	2.67
Quick Ratio	2.14
Debt / Equity	0.03
Debt / EBITDA	0.23
Debt / FCF	-0.44
Interest Coverage	9.28

Financial Efficiency

Return on equity (ROE) is 3.79% and return on invested capital (ROIC) is 2.71%.

Return on Equity (ROE)	3.79%
Return on Assets (ROA)	2.29%
Return on Capital (ROIC)	2.71%
Revenue Per Employee	372,838
Profits Per Employee	32,938
Employee Count	515
Asset Turnover	0.35
Inventory Turnover	2.24

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +66.56% in the last 52 weeks. The beta is 0.78, so Celon Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.78
52-Week Price Change	+66.56%
50-Day Moving Average	26.04
200-Day Moving Average	23.41
Relative Strength Index (RSI)	41.56
Average Volume (20 Days)	21,236

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celon Pharma had revenue of PLN 209.54 million and earned 18.51 million in profits. Earnings per share was 0.35.

Revenue	209.54M
Gross Profit	145.43M
Operating Income	21.87M
Pretax Income	27.27M
Net Income	18.51M
EBITDA	49.60M
EBIT	21.87M
Earnings Per Share (EPS)	0.35

Balance Sheet

The company has 103.28 million in cash and 14.33 million in debt, giving a net cash position of 88.96 million or 1.65 per share.

Cash & Cash Equivalents	103.28M
Total Debt	14.33M
Net Cash	88.96M
Net Cash Per Share	1.65
Equity (Book Value)	516.25M
Book Value Per Share	9.59
Working Capital	120.99M

Cash Flow

In the last 12 months, operating cash flow was -17.18 million and capital expenditures -15.64 million, giving a free cash flow of -32.82 million.

Operating Cash Flow	-17.18M
Capital Expenditures	-15.64M
Free Cash Flow	-32.82M
FCF Per Share	-0.61

Margins

Gross margin is 69.41%, with operating and profit margins of 10.44% and 8.83%.

Gross Margin	69.41%
Operating Margin	10.44%
Pretax Margin	13.01%
Profit Margin	8.83%
EBITDA Margin	23.67%
EBIT Margin	10.44%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 0.32%.

Dividend Per Share	0.08
Dividend Yield	0.32%
Dividend Growth (YoY)	-11.11%
Years of Dividend Growth	n/a
Payout Ratio	24.82%
Buyback Yield	-4.00%
Shareholder Yield	-3.68%
Earnings Yield	1.39%
FCF Yield	-2.44%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Celon Pharma has an Altman Z-Score of 6.11.

Altman Z-Score	6.11
Piotroski F-Score	n/a